Founded in 2020, New York City-based Antelope Surgical Solutions develops small-molecule radiopharmaceuticals that help identify and treat cancer, including agents designed to make tumors glow during surgery. The pre-revenue, clinical-stage company operates a GMP manufacturing facility with robotic high-throughput synthesis and has received FDA IND clearance for its lead agent, AS1986NS.
FDA IND Clearance
Registration
FDA IND Approval for AS1986NS
Registration
SOFIE BiosciencesSOFIE Biosciences develops and manufactures radiopharmaceuticals for molecular imaging and theranostic applications. Founded in 2006, the company combines a radiopharmacy production and distribution network with contract manufacturing and the development of FAPI diagnostic compounds. Its radiopharmacy sites produce and deliver imaging agents across the United States, while its contract manufacturing work supports research, clinical trials, and commercial supply.COLONIE, NY
OptosurgicalFounded in 2019, Optosurgical is a Columbia, Maryland startup developing surgical-vision technology for clinicians working in minimally invasive procedures. Its research centers on making critical anatomy visible in real time, including through the hANDY-i system for parathyroid visualization. The company’s work has received NIH and ARPA-H SBIR Phase II support and is being developed with clinical partners including Johns Hopkins Hospital.COLUMBIA, MD
Ultrasonic Medical Mapping, IncBethesda-based Ultrasonic Medical Mapping develops radiation-free cancer-detection technology, adapting a mature method from defense and aerospace testing for medical use. Its patented system is focused on finding pancreatic tumors earlier and at smaller sizes than existing imaging and non-imaging technologies, and the company has built a preclinical prototype for technical validation. UMM is now working toward clinical testing with hospital and clinical partners.BETHESDA, MD
Akrotome ImagingIncorporated in Delaware in late 2008, Cleveland-based Akrotome Imaging develops fluorescent molecular probes that help surgeons see cancer and its margins during resection. Its patented FIRE platform uses quenched probes that activate when they encounter tumor-associated enzymes, with the flexibility to be applied in the operating room and used alongside a near-infrared imaging system. The company’s current team has been in place since 2012 and is translating the technology toward breast and non-melanoma skin cancer applications.CLEVELAND, OH